Genomic Health, Pfizer to Co-Develop Renal Cancer Dx Based on Oncotype DX Platform

The alliance pairs Genomic Health’s tried-and-tested Oncotype DX diagnostic platform with Pfizer’s sway with payors, which could widen adoption of the technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories